Direkt zum Inhalt
Merck

269476

Sigma-Aldrich

N-Acetylprocainamid

≥99%

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Lineare Formel:
4-(CH3CONH)C6H4CONHCH2CH2N(C2H5)2
CAS-Nummer:
Molekulargewicht:
277.36
MDL-Nummer:
UNSPSC-Code:
12352100
PubChem Substanz-ID:
NACRES:
NA.22

Assay

≥99%

Form

solid

mp (Schmelzpunkt)

138-140 °C (lit.)

Löslichkeit

soluble 1%, clear, colorless to faintly yellow (1N HCl)

SMILES String

CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1

InChI

1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)

InChIKey

KEECCEWTUVWFCV-UHFFFAOYSA-N

Allgemeine Beschreibung

The relaxant effects of N-acetylprocainamide on bovine tracheal smooth muscle was studied.

Anwendung

N-acetylprocainamide (NAPA) was used as a model drug in the study of establishing a quantitative approach to predict the renal clearances of basic drugs using N-1-methylnicotinamide (NMN).

Piktogramme

Exclamation mark

Signalwort

Warning

Gefahreneinstufungen

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Gloves


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Y L He et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 13(3), 303-308 (2001-06-01)
The dosage regimen of a drug eliminated predominantly through the kidney need to be adjusted for the patients with renal disease. The objective of the present study was to establish a quantitative approach to precisely predicting the renal clearances of
Multicenter evaluation of the Abbott AxSYM procainamide and N-acetylprocainamide assays: comparison with Abbott TDx/TDxFLx, Syva EMIT 2000, DuPont ACA, and HPLC methods.
H M Azzazy et al.
Clinical biochemistry, 31(1), 55-58 (1998-04-29)
J E Tisdale et al.
Therapeutic drug monitoring, 18(6), 693-697 (1996-12-01)
The objective of this study was to compare the precision and accuracy of fluorescence polarization immunoassay (FPIA) with high-performance liquid chromatography (HPLC) for measurement of procainamide (PA) and N-acetylprocainamide (NAPA) concentrations in urine. To determine the correlation between FPIA and
M Boucher et al.
Journal of autonomic pharmacology, 18(2), 83-87 (1998-09-08)
1. The cardiac anticholinergic effects of procainamide (1 mg kg(-1) min(-1)) and its N-acetylated metabolite (NAPA) at equimolar dose (1.16 mg kg(-1) min(-1)) were studied using in vivo experimental pharmacological and in vitro radioligand binding studies. 2. Procainamide and NAPA
Application of capillary electrophoresis to the in vitro assessment of drug metabolism.
C M Hill et al.
Biochemical Society transactions, 23(3), 432S-432S (1995-08-01)

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.